Lexicon Pharmaceuticals LXRX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's other income, net (note 6)?
- Lexicon Pharmaceuticals (LXRX) reported other income, net (note 6) of $1.54M in Q1 2026.
- How has Lexicon Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Lexicon Pharmaceuticals's other income, net (note 6) decreased by 30.5% year-over-year, from $2.22M to $1.54M.
- What is the long-term trend for Lexicon Pharmaceuticals's other income, net (note 6)?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's other income, net (note 6) has grown at a 167.9% compound annual growth rate (CAGR), from $134K to $6.91M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.